This article has been verified for CPD. Click the button below to answer a few
short questions and download a form to be included in your CPD folder.
Corneal confocal microscopy (CCM) is an advanced, non-invasive imaging technique that has become a powerful tool in ophthalmology and beyond. By generating high-resolution images of the corneal nerves, CCM offers a unique window into the health of small nerve fibres throughout the body.
Although widely used to study diabetic neuropathy, this technology has since been applied to a variety of systemic and neurological conditions [1–10]. Its ability to quantify corneal nerve morphology in vivo makes it a promising biomarker for diagnosing, monitoring and researching diseases that involves small fibre dysfunction.
The corneal nerves
The cornea – the transparent anterior layer of the eye – is the most densely innervated tissue in the human body. It contains approximately 7000 to 16,000 nerve fibres per square millimetre, making it 300 to 600 times more densely innervated than the skin [11]. These nerve fibres form a distinctive sub-basal nerve plexus and play vital roles in sensing pain, temperature and mechanical stimuli, as well as in maintaining corneal integrity and homeostasis [12].
Corneal nerves are primarily derived from the ophthalmic branch of the trigeminal nerve. However, the peripheral limbal and stromal regions also receive a smaller contribution from autonomic sympathetic fibres [13]. Structurally, corneal nerves consist of two main types of small sensory nerve fibres [14]:
- Thinly myelinated Aδ-fibres, which mediate rapid, sharp responses to mechanical stimuli and contribute to reflex tearing and blinking
- Small unmyelinated C-fibres, which respond to slower, more persistent stimuli such as thermal and chemical irritation.
These nerves are not just passive messengers of sensory information; they actively participate in regulating the cornea’s structure and function by releasing neurotrophic factors, including nerve growth factor (NGF), which promotes wound healing and maintains corneal epithelial integrity [12]. Owing to their superficial location, high nerve density and close anatomical association with the peripheral nervous system, corneal nerves offer a unique and clinically meaningful window into small fibre integrity in both ocular and systemic disease.
They are easily accessible via non-invasive imaging techniques such as CCM, which enables direct, in vivo visualisation and quantification of these nerves. Furthermore, the exceptionally high density of corneal innervation – far exceeding that of the skin – enhances the sensitivity of CCM in detecting early or subclinical small fibre pathology.
What is CCM?
Corneal confocal microscopy is a non-invasive, reproducible and high-resolution imaging technique that enables direct, real-time visualisation of the corneal microstructures at the cellular level. By employing a confocal optical system, CCM eliminates out-of-focus light through the use of a spatial pinhole, thereby enhancing image contrast and axial resolution. This allows for the precise imaging of discrete corneal layers, most notably the sub-basal nerve plexus.
First introduced in the mid-1990s, CCM was initially used for early detection of small fibre neuropathy in individuals with diabetes, particularly through the quantification of corneal nerve fibre density, length and branching patterns [15–17]. Since then, its applications have extended beyond diabetes to encompass a range of systemic and neurological disorders, including chemotherapy-induced peripheral neuropathy [18], chronic inflammatory demyelinating polyneuropathy [5], multiple sclerosis [1], Parkinson’s disease [7] and amyotrophic lateral sclerosis [19]. Furthermore, CCM is particularly sensitive to early small fibre pathology, often detecting subclinical changes prior to clinical conventional testing, positioning CCM as a valuable biomarker for both clinical diagnostics and longitudinal research.
By allowing clinicians and researchers to observe nerve fibre degeneration and regeneration directly, CCM bridges the gap between clinical examination and microscopic pathology and has done so across diverse populations and disease states.
The CCM device and methodology
The most widely utilised platform for CCM is the Heidelberg Retina Tomograph III equipped with the Rostock Cornea Module (HRT III-RCM). This system employs a high-resolution confocal microscope with a water-immersion objective. This system uses a high-resolution confocal microscope, achieving approximately 680x magnification and enables detailed imaging of the sub-basal nerve plexus as well as other corneal microstructures with high contrast and axial resolution [20]. The typical CCM procedure consists of four main steps [21]:
1. Preparation
The examination begins with the instillation of topical anaesthetic drops and viscous tear gel to minimise ocular discomfort and suppress the blink reflex. Additional gel is used as a coupling agent between the objective lens and the sterile Tomo-Cap to ensure optimal contact and minimise artefacts.
2. Imaging
The microscope’s objective lens is gently positioned against the cornea. Images are captured by rapidly scanning the central cornea and inferior whorl region, typically acquiring 5–8 high-quality, non-overlapping images for each eye. In some cases, variations in the number of images and scan types are employed depending on the study protocol or clinical preference. These images are captured with high resolution to ensure clarity and minimise artefacts.
3. Analysis
These images are then analysed using dedicated software to assess nerve morphology. Several quantitative parameters can be measured, including:
- Corneal nerve fibre density (CNFD): the number of main nerve fibres per square millimetre (no./mm²)
- Corneal nerve fibre length (CNFL): the total length of all nerves and branches within a square millimetre (mm/mm²)
- Corneal nerve branch density (CNBD): the number of nerve branches that sprout from main nerve fibres (no./mm²).
4. Interpretation
The resulting data is compared to established normative values [22]. Alterations in CNFD, CNFL or CNBD can provide insights into the presence and severity of small fibre neuropathy, making CCM a valuable diagnostic and monitoring tool.
Applications in clinical and research settings
Although this article does not focus on specific diseases, it is important to mention that CCM has found a home in multiple clinical contexts. Beyond its initial role in diabetes, CCM is now being explored in:
- Peripheral neuropathies such as chemotherapy-induced neuropathy [18], hereditary sensory neuropathy and autoimmune neuropathies
- Neurodegenerative diseases including multiple sclerosis, Parkinson’s disease, Alzheimer’s disease and other forms of dementia
- Research into small fibre pathology to develop better diagnostic tools and potential therapies.
The corneal nerves’ remarkable similarity to small nerve fibres in the skin and other organs makes CCM findings broadly applicable to peripheral nerve health in general.
Limitations and future directions
While CCM offers considerable promise, its widespread clinical adoption is limited by several factors, the most significant of which is the need for specialist expertise. Accurate image acquisition, appropriate selection of representative frames and reliable interpretation all require trained personnel, which may restrict its use outside specialist centres.
Although manual analysis remains a source of variability, the development of automated software, such as ACCMetrics (University of Manchester, UK), has helped to improve reproducibility and reduce observer bias.
Cost also remains a consideration, as the initial investment in CCM equipment can be substantial, though this may be offset by the long-term benefits of early detection and monitoring. In addition, corneal nerve morphology may vary with age, ocular surface pathology and ethnicity, which underscores the importance of using well-validated normative datasets when interpreting results.
Looking ahead, the integration of artificial intelligence, alongside efforts to standardise acquisition protocols and expand normative reference ranges, will be key to enhancing diagnostic accuracy and facilitating broader implementation of CCM in both research and routine clinical settings.
Notably, the HRT III-RC has been officially discontinued by the manufacturer. Although Heidelberg Engineering has committed to providing technical support and spare parts for most systems until December 2029, the discontinuation raises important considerations for the future of CCM research. The HRT III-RCM remains the most extensively validated device for corneal nerve imaging. Its eventual unavailability may limit methodological consistency, particularly in multicentre trials or longitudinal studies. The manufacturer has not released detailed reasons for the withdrawal, but it likely reflects a shift in focus towards newer imaging technologies, combined with regulatory and supply chain factors. These developments highlight an urgent need to validate alternative confocal systems to ensure continuity, comparability and sustainability of CCM-based research and clinical practice beyond the current lifecycle of the HRT III-RCM.
Conclusion
Corneal confocal microscopy is a transformative technology that has redefined how we visualise and quantify small fibre nerve health. Its high-resolution, real-time images of the cornea’s intricate nerve plexus have proven invaluable in diagnosing and monitoring small fibre neuropathy across a range of diseases [23]. While challenges remain, the continuing refinement of CCM and the development of AI-driven analysis tools promise to expand its role as a vital biomarker for peripheral nerve health [24]. As CCM continues to evolve, it will undoubtedly shape the future of research, diagnosis and treatment in ophthalmology and neurology alike.
References
1. Fernandes D, Luis M, Cardigos J, et al. Corneal subbasal nerve plexus evaluation by in vivo confocal microscopy in multiple sclerosis: a potential new biomarker. Curr Eye Res 2021;46(10):1452–9.
2. Bitirgen G, Akpinar Z, Malik RA, Ozkagnici A. Use of corneal confocal microscopy to detect corneal nerve loss and increased dendritic cells in patients with multiple sclerosis. JAMA Ophthalmol 2017;135(7):777–82.
3. Khan A, Li Y, Ponirakis G, et al. Corneal immune cells are increased in patients with multiple sclerosis. Transl Vis Sci Technol 2021;10(4):19.
4. Testa V, De Santis N, Scotto R, et al. Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study. J Clin Neurosci 2020;81:139–43.
5. Schneider C, Bucher F, Cursiefen C, et al. Corneal confocal microscopy detects small fiber damage in chronic inflammatory demyelinating polyneuropathy (CIDP). J Peripher Nerv Syst 2014;19(4):322–7.
6. Petropoulos IN, Ponirakis G, Khan A, et al. Corneal confocal microscopy: ready for prime time. Clin Exp Optom 2020;103(3):265–77.
7. Che NN, Yang HQ. Potential use of corneal confocal microscopy in the diagnosis of Parkinson’s disease associated neuropathy. Transl Neurodegener 2020;9(1):28.
8. Lim SH, Ferdousi M, Maltenes A, et al. Corneal confocal microscopy detects small fibre neurodegeneration in Parkinson’s disease using automated analysis. Sci Rep 2020;10(1):20147.
9. Lim SH, Ferdousi M, Kalteniece A, et al. Corneal confocal microscopy identifies Parkinson’s disease with more rapid motor progression. Mov Disord 2021;36(8):1927–34.
10. Podgorny PJ, Suchowersky O, Romanchuk KG, Feasby TE. Evidence for small fiber neuropathy in early Parkinson’s disease. Parkinsonism Relat Disord 2016;28:94–9.
11. Gadjeva M. Neuropathy: Looking into nerve damage in the cornea. eLife 2019;8:e51497.
12. Shaheen BS, Bakir M, Jain S. Corneal nerves in health and disease. Surv Ophthalmol 2014;59(3):263–85.
13. Yang AY, Chow J, Liu J. Corneal innervation and sensation: The eye and beyond. Yale J Biol Med 2018;91(1):13–21.
14. Arcilla CK, Tadi P. Neuroanatomy, unmyelinated nerve fibers. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
15. Maddaloni E, Sabatino F. In vivo corneal confocal microscopy in diabetes: Where we are and where we can get. World J Diabetes 2016;7(17):406–11.
16. Petropoulos IN, Ponirakis G, Ferdousi M, et al. Corneal confocal microscopy: A biomarker for diabetic peripheral neuropathy. Clin Ther 2021;43(9):1457–75.
17. Dhage S, Ferdousi M, Adam S, et al. Corneal confocal microscopy identifies small fibre damage and progression of diabetic neuropathy. Sci Rep 2021;11(1):1859.
18. Ferdousi M, Azmi S, Petropoulos IN, et al. Corneal confocal microscopy detects small fibre neuropathy in patients with upper gastrointestinal cancer and nerve regeneration in chemotherapy induced peripheral neuropathy. PLoS One 2015;10(10):e0139394.
19. Fu J, He J, Zhang Y, et al. Small fiber neuropathy for assessment of disease severity in amyotrophic lateral sclerosis: Corneal confocal microscopy findings. Orphanet J Rare Dis 2022;17(1):7
20. Petroll WM, Robertson DM. In vivo confocal microscopy of the cornea: New developments in image acquisition, reconstruction and analysis using the HRT-rostock corneal module. Ocul Surf 2015;13(3):187–203.
21. Tavakoli M, Malik RA. Corneal confocal microscopy: a novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. J Vis Exp 2011;47:2194.
22. Tavakoli M, Ferdousi M, Petropoulos IN, et al. Normative values for corneal nerve morphology assessed using corneal confocal microscopy: a multinational normative data set. Diabetes Care 2015;38(5):838–43.
23. Petropoulos IN, Bitirgen G, Ferdousi M, et al. Corneal confocal microscopy to image small nerve fiber degeneration: ophthalmology meets neurology. Front Pain Res (Lausanne) 2021;2:725363.
24. Alam U, Anson M, Meng Y, et al. Artificial Intelligence and corneal confocal microscopy: The start of a beautiful relationship. J Clin Med 2022;11(20):6199.
Declaration of competing interests: None declared.
